- Home
- SABR vs TBPH Comparison
SABR vs TBPH Comparison
Compare SABR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | TBPH |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.0M | 908.9M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SABR | TBPH |
|---|---|---|
| Price | $1.75 | $16.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 5.1M | 911.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 279.13 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $3,866,956,000.00 | $15,386,000.00 |
| Revenue This Year | $7.51 | $8.46 |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $86.00 | ★ N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $0.81 | $10.82 |
| 52 Week High | $3.30 | $21.03 |
Technical Indicators
Market Signals| Indicator | SABR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 49.67 |
| Support Level | $1.72 | $16.17 |
| Resistance Level | $1.99 | $17.21 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 10.78 | 8.33 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.